Dr. Andrew Brohl at ASCO 2023: Abstract No. 9534

2 Views
administrator
administrator
07/17/23

At ASCO 2023, Moffitt's Dr. Andrew Brohl discusses a phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next